• REEM HASABALLAH ALHASANI Department of Biology, Faculty of Applied Science, Umm Al-Qura University, Makkah, Saudi Arabia
  • NORAH A. ALTHOBAITI Biology Department, College of Science and Humanities-Al Quwaiiyah, Shaqra University, Al Quwaiiyah 19257, Saudi Arabia
  • SALMA SALEH ALRDAHE Department of Biology, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia



prostatitis, Prostate cancer, magnetic resonance, hyperplasia


Prostate cancer (PC) is the most common malignancy among men and is the fifth leading cause of cancer-related death in men worldwide. The present study aims to systematically review the ability of magnetic resonance spectroscopy (MRS) to differentiate between benign and malignant prostate lesions. According to the 06- PRISMA guideline, we searched in five English databases, including Scopus, PubMed, Web of Science, EMBASE, and Google Scholar without time limitation for publications related to the role of The role of magnetic resonance spectroscopy for prostate cancer diagnosis. The searched words and terms were: “prostate cancer”, “prostatitis”, “magnetic resonance spectroscopy”, “benign prostate hyperplasia”, “malignant prostate hyperplasia”, “comparison”. Totally 1927 papers were identified by database searching. Out of these papers, 261 papers were discarded because of duplication. Of the remaining 1666 papers, 1604 papers were discarded because of the inadequate information and the ones in which the abstract was submitted in congresses as preceding papers, conferences, and editorials without full text. Out of the remaining 62 papers which were studied for eligibility, 52 papers were removed for a number of reasons including inconsistency between methods with results, incorrect interpretation of the results, poor methodology, etc. Finally, 10 papers were included in this present study. In general, based on the results of the review of articles, MRS has optimal sensitivity, specificity and accuracy in diagnosing prostate cancer and differentiating it from benign prostate hyperplasia in comparison with other diagnostic and pathological methods. Due to the small number of studies related to the sensitivity and specificity of MRS, further checking was not possible to confirm these results. Therefore, further studies in this regard are recommended.


Download data is not yet available.


Morgans SC, Holmes OE, Craig J, et al. Long-Term Outcomes of Prostate Radiotherapy for Newly-Diagnosed Metastatic HormoneSensitive Prostate Cancer. Prostate Cancer Prostatic Dis. 2021.

Negoita S, Feuer EJ, Mariotto A, Cronin KA, Petkov VI, Hussey SK, Benard V, et al. Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics. Cancer. 2018;124(13):2801-2814.

Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, Ward EM. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA. 2015;314(19):2054-2061.

Taitt HE. Global Trends and Prostate Cancer: A review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Mens Health. 2018;12(6):1807-1823.

Satapathy, S., Sood, A., Das, C.K. et al. Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer—a systematic review and meta-analysis. Prostate Cancer Prostatic Dis (2021).

Denny DC, SS Y, R V, Fardan M, Iype Ds, K Am. Cardiovascular risk associated with androgen deprivation therapy in advanced prostate cancer. Asian J Pharm Clin Res. 2021;14(8):6-9.

Ferlay J EM, Lam F, Colombet M, Mery L, Pineros M, Znaor A, Soerjomataram I, et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc. fr/today, Accessed 02 February 2019.

Cancer Stat Facts: Prostate Cancer [Internet]. SEER, 2018. Available from: html/prost.html.

Force USPST, Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, et al. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA. 2018;319(18):1901-1913.

Begum SA, Rani S J, Banu A, Pavani A, Yeruva V. Statistics of cancer, 2020 in Indian states: a review on the report from national cancer registry programme. Asian J Pharm Clin Res. 2021;14(6):36-42.

Hosain GM, Sanderson M, Du XL, Chan W, Strom SS. Racial/ethnic differences in predictors of PSA screening in a tri-ethnic population. Cent Eur J Public Health. 2011;19(1):30-34.

Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, Rachinsky I. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate cancer and prostatic diseases. 2012;15(1):45-55.

Aronson WJ, Barnard RJ, Freedland SJ, Henning S, Elashoff D, Jardack PM, Cohen P, et al. Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer. J Urol. 2010;183(1):345-350.

Venkateswaran V, Klotz LH. Diet and prostate cancer: mechanisms of action and implications for chemoprevention. Nat Rev Urol. 2010;7(8):442-453.

Stram DO, Hankin JH, Wilkens LR, Park S, Henderson BE, Nomura AM, Pike MC, et al. Prostate cancer incidence and intake of fruits, vegetables and related micronutrients: the multiethnic cohort study* (United States). Cancer Causes Control. 2006;17(9):1193-1207.

Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007;121(7):1571-1578.

Bass, E.J., Pantovic, A., Connor, M. et al. A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk. Prostate Cancer Prostatic Dis (2020).

Sesso HD, Paffenbarger RS Jr, Lee IM. Alcohol consumption and risk of prostate cancer: The Harvard Alumni Health Study. Int J Epidemiol. 2001 Aug;30(4):749-55. doi: 10.1093/ije/30.4.749. PMID: 11511598.

Taylor ML, Mainous AG 3rd, Wells BJ. Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med. 2005 Jul-Aug;37(7):506-12. PMID: 15988645.

Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013;63(5):800-809.

Descotes JL. Diagnosis of prostate cancer. Asian journal if urology (2019) 6, 129-136.

Alaryani FS, Turki Alrdahe SS. A review of treatment, risk factors, and incidence of colorectal cancer. Int J App Pharm. 2022;14(1):1-6.

Lamy PJ, Allory Y, Gauchez AS, Asselain B, Beuzeboc P, de Cremoux P, et al. Pronostic biomarkers used for localized prostate cancer management: asystematic review. EurUrol Focus 2017;7:30065e72.

Jones D, Friend Ch, Dreher A, Allgar V, Macleod U. The diagnostic test accuracy of rectal examination for prostate cancer diagnosis in symptomatic patients: a systematic review. BMC Family Practice (2018) 19:79

Tyson MD, Arora SS, Scarpato KR, Barocas D. Magnetic resonance-ultrasound fusion prostate biopsy in the diagnosis of prostate cancer. UrolOncol2016;34:326e32.

Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MG. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectalultrasoundguided biopsy: a systematic review and meta-analysis. EurUrol2015;68:438e50.

Martin H, Maurer J, Heverhagen T. Diffusion weighted imaging of the prostate—principles, application, and advances. TranslAndrol Urol. 2017 Jun; 6(3): 490-498.

Barentsz J, de Rooij M, Villeirs G, Weinreb J. Prostate Imaging-Reporting and Data System Version 2 and the Implementation of High-quality Prostate Magnetic Resonance Imaging. European urology 2017;72(2):189-91.

Thörmer G, Otto J, Horn L-C, Garnov N, Do M, Franz T, et al. Non-invasive estimation of prostate cancer aggressiveness using diffusion-weighted MRI and 3D proton MR spectroscopy at 3.0 T. ActaRadiologica. 2015;56(1):121-8.

Cornel EB, Smits GAHJ, Oosterhof GON, Karthaus HFM, Debruyne FMJ, Schalken JA, et al. Characterization of Human Prostate-Cancer, Benign Prostatic Hyperplasia and Normal Prostate by in-Vitro H-1 and P-31 Magnetic-Resonance Spectroscopy. Journal of Urology. 1993;150(6):2019-24.

Kurhanewicz J, Vigneron DB, Nelson SJ, Hricak H, MacDonald JM, Konety B, et al. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology. 1995;45(3):459-66.

Kim JK, Kim DY, Lee YH, Sung NK, Chung DS, Kim OD, et al. In vivo differential diagnosis of prostate cancer and benign prostatic hyperplasia: Localized proton magnetic resonance spectroscopy using external-body surface coil. Magnetic resonance imaging. 1998;16(10):1281-8.

García-Segura JM, Sánchez-Chapado M, Ibarburen C, Viaño J, Angulo JC, González J, et al. In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology. Magnetic resonance imaging. 1999;17(5):755-65.

Yue K, Marumoto A, Binesh N, Thomas MA. 2D JPRESS of human prostates using an endorectal receiver coil. Magnetic resonance in medicine. 2002;47(6):1059-64.

Giskeødegård GF, Hansen AF, Bertilsson H, Gonzalez SV, Kristiansen KA, Bruheim P, et al. Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia. British journal of cancer. 2015;113(12):1712-9.

Meier-Schroers M, Kukuk G, Wolter K, Decker G, Fischer S, Marx C, et al. Differentiation of prostatitis and prostate cancer using the Prostate Imaging - Reporting and Data System (PI-RADS). European Journal of Radiology. 2016;85(7):1304-11.

Zhang TH, Hu CH, Chen JX, Xu ZD, Shen JK. Differentiation Diagnosis of Hypo-Intense T2 Area in Unilateral Peripheral Zone of Prostate Using Magnetic Resonance Spectroscopy (MRS): Prostate Carcinoma versus Prostatitis. Medical science monitor : international medical journal of experimental and clinical research. 2017;23:3837-43.

Zhang XQ, Yu XR, Du ZL, Miao XF, Lu J, Zhou Q. Three-dimensional proton magnetic resonance spectroscopy and diffusion-weighted imaging in the differentiation of incidental prostate carcinoma from benign prostate hyperplasia. Oncology letters. 2018;15(5):6541-6.

Mazaheri Y, Amita Shukla-Davl,et al. Characterization of Prostate Cancer with MR Spectroscopic Imaging and Diffusion weighted Imaging at 3 Tesla. doi:10.1016/j.mri.2018.08.025

Barentsz J, de Rooij M, Villeirs G, Weinreb J. Prostate Imaging-Reporting and Data System Version 2 and the Implementation of High-quality Prostate Magnetic Resonance Imaging. European urology 2017;72(2):189-91.

Kobus T, van der Laak JA, Maas MC, Hambrock T, Bruggink CC, Hulsbergen-van de Kaa CA, et al. Contribution of Histopathologic Tissue Composition to Quantitative MR Spectroscopy and Diffusion-weighted Imaging of the Prostate. Radiology 2015:142889

Barentsz J, de Rooij M, Villeirs G, Weinreb J. Prostate Imaging-Reporting and Data System Version 2 and the Implementation of High-quality Prostate Magnetic Resonance Imaging. European urology 2017;72(2):189-91.

Robatjazi M, Pashazadeh A.M, Karimi H, Assadi M. Molecular imaging with Magnetic Resonance Spectroscopy (MRS). ISMJ 2015; 18(1): 210-221.

Carter HB. Diagnosis and staging of prostate cancer. Campbell's urology. 1998;3:2519-37.

Ikonen S, Kivisaari L, Tervahartiala P, Vehmas T, Taari K, Rannikko S. Prostatic MR imaging: accuracy in differentiating cancer from other prostatic disorders. Actaradiologica. 2001;42(4):348-54.

Hricak H, White S, Vigneron D, Kurhanewicz J, Kosco A, Levin D, et al. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal--pelvic phased-array coils. Radiology. 1994;193(3):703-9.

Jager GJ, Severens JL, Thornbury JR, de la Rosette JJ, Ruijs SH, Barentsz JO. Prostate cancer staging: should MR imaging be used?—A decision analytic approach. Radiology. 2000;215(2):445-51.

Claus FG, Hricak H, Hattery RR. Pretreatment evaluation of prostate cancer: role of MR imaging and 1H MR spectroscopy. Radiographics. 2004;24(suppl_1):S167-S80.

Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, et al. Diffusionweighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009;11(2):102-25

Kristen L. Zakiana, William Hatfieldb, Omer Arasc, Kun Caod, DeryaYakare, Debra A. Goldmanf ,Chaya S. Moskowitzg, Amita Shukla-Daveh, Yousef MazaheriTehranii , Samson Finej , James Easthamk , and HedvigHricakl.Prostate MRSI Predicts outcome in Radical Prostatectomy patients. MagnReson Imaging. Author manuscript; available in PMC 2017 June 01.

Zakian KL, Sircar K, Hricak H, Chen H-N, Shukla-Dave A, Eberhardt S, et al. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology. 2005;234(3):804-14.

Zhang XQ, Yu XR, Du ZL, Miao XF, Lu J, Zhou Q. Three-dimensional proton magnetic resonance spectroscopy and diffusion-weighted imaging in the differentiation of incidental prostate carcinoma from benign prostate hyperplasia. Oncology letters. 2018;15(5):6541-6.



How to Cite




Review Article(s)